Phase I AZD2171 [cediranib] in patients with relapsed or refractory AML [acute myeloid leukaemia] and elderly patients with denovo or secondary AML
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Cediranib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors AstraZeneca
- 13 Aug 2007 New trial record.